PVR and glioblastoma: Blocking CD155/PVR/Necl-5 with anti-CD155/PVR/Necl-5 antibodies (20) and the knockdown of CD155/PVR/Necl-5 by RNAi (27) resulted in decreased migration of glioblastoma cells.